Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2008 1
2011 1
2012 2
2013 1
2014 1
2015 1
2016 2
2017 1
2018 3
2019 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
How Do Patients Respond to Genetic Testing for Age-related Macular Degeneration?
McCarty CA, Fuchs MJ, Lamb A, Conway P. McCarty CA, et al. Optom Vis Sci. 2018 Mar;95(3):166-170. doi: 10.1097/OPX.0000000000001188. Optom Vis Sci. 2018. PMID: 29424826 Free PMC article.
SIGNIFICANCE: The American Academy of Ophthalmology currently recommends against routine genetic testing for complex diseases such as age-related macular degeneration (AMD). The results of this study demonstrate that patients are v …
SIGNIFICANCE: The American Academy of Ophthalmology currently recommends against routine genetic testing for complex diseases …
Patient Use of Dietary Supplements, Home Monitoring, or Genetic Testing for Nonneovascular Age-Related Macular Degeneration.
Tsou BC, Liu TYA, Kong J, Bressler SB, Arevalo JF, Brady CJ, Handa JT, Meyerle CB, Scott AW, Wenick AS, Bressler NM. Tsou BC, et al. J Vitreoretin Dis. 2021 Apr 26;5(5):389-395. doi: 10.1177/2474126421989228. eCollection 2021 Sep-Oct. J Vitreoretin Dis. 2021. PMID: 37008702 Free PMC article.
PURPOSE: This work evaluated the use and type of dietary supplements and home monitoring for nonneovascular age-related macular degeneration (AMD), as well as the prevalence of genetic testing among patients with AMD. ...Genetic
PURPOSE: This work evaluated the use and type of dietary supplements and home monitoring for nonneovascular age-related mac
Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degeneration.
Balikova I, Postelmans L, Pasteels B, Coquelet P, Catherine J, Efendic A, Hosoda Y, Miyake M, Yamashiro K; ANGEL study group members; Thienpont B, Lambrechts D. Balikova I, et al. BMJ Open Ophthalmol. 2019 Dec 17;4(1):e000273. doi: 10.1136/bmjophth-2019-000273. eCollection 2019. BMJ Open Ophthalmol. 2019. PMID: 31909188 Free PMC article.
OBJECTIVE: Age-related macular degeneration (ARMD) is a leading cause of visual impairment. ...Of six SNPs tested for replication, one was significant although not after multiple testing correction. CONCLUSION: Identifying genetic variant …
OBJECTIVE: Age-related macular degeneration (ARMD) is a leading cause of visual impairment. ...Of six SNPs teste …
Clinical characteristics of familial and sporadic age-related macular degeneration: differences and similarities.
Saksens NT, Kersten E, Groenewoud JM, van Grinsven MJ, van de Ven JP, Sánchez CI, Schick T, Fauser S, den Hollander AI, Hoyng CB, Boon CJ. Saksens NT, et al. Invest Ophthalmol Vis Sci. 2014 Oct 9;55(11):7085-92. doi: 10.1167/iovs.14-14659. Invest Ophthalmol Vis Sci. 2014. PMID: 25301878
PURPOSE: We describe the differences and similarities in clinical characteristics and phenotype of familial and sporadic patients with age-related macular degeneration (AMD). METHODS: We evaluated data of 1828 AMD patients and 1715 contro …
PURPOSE: We describe the differences and similarities in clinical characteristics and phenotype of familial and sporadic patients wit …
Phenotypic Characterization of Complement Factor H R1210C Rare Genetic Variant in Age-Related Macular Degeneration.
Ferrara D, Seddon JM. Ferrara D, et al. JAMA Ophthalmol. 2015 Jul;133(7):785-91. doi: 10.1001/jamaophthalmol.2015.0814. JAMA Ophthalmol. 2015. PMID: 25880396 Free PMC article.
IMPORTANCE: The complement factor H R1210C rare variant confers the strongest genetic risk for age-related macular degeneration and earlier age at onset; however, its associated phenotype has not been well characterized. ...For this retro …
IMPORTANCE: The complement factor H R1210C rare variant confers the strongest genetic risk for age-related macular
An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age-Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure.
Hallam D, Collin J, Bojic S, Chichagova V, Buskin A, Xu Y, Lafage L, Otten EG, Anyfantis G, Mellough C, Przyborski S, Alharthi S, Korolchuk V, Lotery A, Saretzki G, McKibbin M, Armstrong L, Steel D, Kavanagh D, Lako M. Hallam D, et al. Stem Cells. 2017 Nov;35(11):2305-2320. doi: 10.1002/stem.2708. Epub 2017 Oct 9. Stem Cells. 2017. PMID: 28913923 Free PMC article.
Age-related macular degeneration (AMD) is the most common cause of blindness, accounting for 8.7% of all blindness globally. ...Taken together, our data indicate that the patient specific iPSC model provides a robust platform for understanding t
Age-related macular degeneration (AMD) is the most common cause of blindness, accounting for 8.7% of all blindne
Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
Wang VM, Rosen RB, Meyerle CB, Kurup SK, Ardeljan D, Agron E, Tai K, Pomykala M, Chew EY, Chan CC, Tuo J. Wang VM, et al. Mol Vis. 2012;18:2578-85. Epub 2012 Oct 20. Mol Vis. 2012. PMID: 23112570 Free PMC article.
PURPOSE: The use of anti-vascular endothelial growth factor (anti-VEGF) therapy, with drugs such as ranibizumab and bevacizumab, to treat neovascular age-related macular degeneration (nAMD) produces an effective but widely variable response. ...Pati
PURPOSE: The use of anti-vascular endothelial growth factor (anti-VEGF) therapy, with drugs such as ranibizumab and bevacizumab, to treat ne …
CRB1 related retinal degeneration with novel mutation.
Ghiam BK, Wood EH, Thanos A, Randhawa S. Ghiam BK, et al. Am J Ophthalmol Case Rep. 2020 Apr 9;18:100699. doi: 10.1016/j.ajoc.2020.100699. eCollection 2020 Jun. Am J Ophthalmol Case Rep. 2020. PMID: 32322752 Free PMC article.
PURPOSE: To describe novel and previously unreported genetic mutations in the CRB1 gene in a patient with retinal dystrophy. ...This case is phenotypically unique in that CME was refractory to therapy, while CME in CRB1 related maculopathy typically respon
PURPOSE: To describe novel and previously unreported genetic mutations in the CRB1 gene in a patient with retinal dystrophy. . …
Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
Teper SJ, Nowinska A, Pilat J, Wylegala E. Teper SJ, et al. Photodiagnosis Photodyn Ther. 2016 Mar;13:108-113. doi: 10.1016/j.pdpdt.2016.01.006. Epub 2016 Jan 15. Photodiagnosis Photodyn Ther. 2016. PMID: 26780119 Clinical Trial.
BACKGROUND: Treatment of neovascular age-related macular degeneration (nAMD) remains a major challenge in ophthalmology. It is essential to determine which of VEGF inhibition non-responders can benefit from photodynamic therapy (PDT). As AMD is …
BACKGROUND: Treatment of neovascular age-related macular degeneration (nAMD) remains a major challenge in ophtha …
Central areolar choroidal dystrophy (CACD) and age-related macular degeneration (AMD): differentiating characteristics in multimodal imaging.
Smailhodzic D, Fleckenstein M, Theelen T, Boon CJ, van Huet RA, van de Ven JP, Den Hollander AI, Schmitz-Valckenberg S, Hoyng CB, Weber BH, Holz FG, Klevering BJ. Smailhodzic D, et al. Invest Ophthalmol Vis Sci. 2011 Nov 21;52(12):8908-18. doi: 10.1167/iovs.11-7926. Invest Ophthalmol Vis Sci. 2011. PMID: 22003107 Clinical Trial.
To detect discerning features, the morphologic changes in CACD patients and in AMD patients were assessed with confocal scanning laser ophthalmoscopy (cSLO), fundus autofluorescence (FAF), and spectral-domain optical coherence tomography (SD-OCT). METHODS: A total o …
To detect discerning features, the morphologic changes in CACD patients and in AMD patients were assessed with confocal scanni …
18 results